Clinical Trials Logo

Primary Cervical Dystonia clinical trials

View clinical trials related to Primary Cervical Dystonia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03369613 Completed - Clinical trials for Primary Cervical Dystonia

Transcranial Electrical Stimulation for Cervical Dystonia

Start date: October 27, 2017
Phase: N/A
Study type: Interventional

There are two phases. Phase I: A single visit which includes a screening, clinical scales, and a MRI scan with simultaneous tES/sham tES in a randomized block design. Enrolls both Cervical Dystonia (CD) patients and healthy controls. Phase II: 5 consecutive days of 30-90 min visits to campus for tES or sham tES. Transcranial magnetic stimulation (TMS) measures and clinical scales will also be included on Day 1 and Day 5 visits. Enrolls only CD patients.

NCT ID: NCT02542839 Completed - Dystonia Clinical Trials

rTMS and Botulinum Toxin in Primary Cervical Dystonia

Start date: November 2015
Phase: N/A
Study type: Interventional

Primary cervical dystonia (PCD) is the most common form of focal dystonia. PCD is frequently reported as a source of disability, decreased quality of life, and social stigma. Botulinum toxin (BoNT) is the gold standard treatment for PCD. The average duration of benefits from BoNT injections was about 9.5 weeks and BoNT treatment is known to provide only pure symptomatic benefits and does not seem to modify the disease pathophysiology. The investigator plans to use repetitive transcranial magnetic stimulation (rTMS) therapy as an adjunctive therapy in combination with BoNT injections as a novel approach to treat PCD. The primary goal of this study is to compare standard treatment with BoNT versus BoNT combined with a two week course of rTMS.

NCT ID: NCT02046447 Completed - Clinical trials for Primary Cervical Dystonia

Neuroimaging of Dystonia

NID
Start date: May 2014
Phase: N/A
Study type: Observational

The main purpose of this study is to investigate primary cervical dystonia as compared to healthy control subjects and DYT 1 dystonia as compared to healthy control subjects by examining cognitive measures, physical measures, and structural and functional magnetic resonance imaging (MRI). The secondary aim of this study is to investigate a specific drug therapy for primary cervical dystonia to develop a functional MRI (fMRI) research paradigm. The drug, trihexyphenidyl, is FDA approved to treat Parkinson's Disease and is commonly prescribed by physicians as a treatment for symptoms of primary cervical dystonia.